UY31698A - Preparacion solida de desintegracion oral - Google Patents

Preparacion solida de desintegracion oral

Info

Publication number
UY31698A
UY31698A UY0001031698A UY31698A UY31698A UY 31698 A UY31698 A UY 31698A UY 0001031698 A UY0001031698 A UY 0001031698A UY 31698 A UY31698 A UY 31698A UY 31698 A UY31698 A UY 31698A
Authority
UY
Uruguay
Prior art keywords
oral disintegration
solid preparation
solid oral
fine granules
disintegration preparation
Prior art date
Application number
UY0001031698A
Other languages
English (en)
Inventor
Kurasawa Takashi
Watanabe Yasuko
Omachi Yoshihiro
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40791576&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY31698(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY31698A publication Critical patent/UY31698A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención provee una preparación sólida de desintegración oral tales como un comprimido producido formando comprimidos los gránulos finos que muestran una liberación controlada de un principio activo para uso faramcéutico y un aditivo, y similares, y la preparación sólida de desintegración oral que contiene gránulos finos recubiertos con una capa de recubrimiento que contiene un polímero que produce una película de recubrimiento que tiene una elongación en la ruptura de alrededor de 100 - alrededor de 700 %.
UY0001031698A 2008-03-11 2009-03-10 Preparacion solida de desintegracion oral UY31698A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008061673 2008-03-11
JP2008334920 2008-12-26

Publications (1)

Publication Number Publication Date
UY31698A true UY31698A (es) 2009-11-10

Family

ID=40791576

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001031698A UY31698A (es) 2008-03-11 2009-03-10 Preparacion solida de desintegracion oral

Country Status (26)

Country Link
US (2) US9241910B2 (es)
EP (1) EP2254556A2 (es)
JP (1) JP5604304B2 (es)
KR (1) KR20100129761A (es)
CN (2) CN102026627B (es)
AR (1) AR070863A1 (es)
AU (1) AU2009224254A1 (es)
BR (1) BRPI0909439A2 (es)
CA (1) CA2717947C (es)
CL (1) CL2009000557A1 (es)
CO (1) CO6321224A2 (es)
CR (1) CR11709A (es)
DO (1) DOP2010000273A (es)
EA (1) EA021792B1 (es)
EC (1) ECSP10010538A (es)
GE (1) GEP20135845B (es)
IL (1) IL207989A0 (es)
MA (1) MA32174B1 (es)
MX (1) MX2010009824A (es)
MY (1) MY173730A (es)
NZ (1) NZ588407A (es)
PE (2) PE20091620A1 (es)
TW (1) TWI441658B (es)
UY (1) UY31698A (es)
WO (1) WO2009113703A2 (es)
ZA (1) ZA201006679B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY31698A (es) 2008-03-11 2009-11-10 Takeda Pharmaceutical Preparacion solida de desintegracion oral
CN102119027A (zh) * 2008-06-26 2011-07-06 麦克内尔-Ppc股份有限公司 含有药物活性剂的包衣颗粒
EP3031451B1 (en) * 2009-01-26 2018-03-07 Shin-Etsu Chemical Co., Ltd Wet granulation tableting method using aqueous dispersion of low-substituted hydroxypropyl cellulose
EP2319504A1 (en) * 2009-11-07 2011-05-11 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical solid dosage form
WO2012001705A2 (en) * 2010-06-29 2012-01-05 Cadila Healthcare Limited Pharmaceutical compositions of (r)-lansoprazole
CN103402500A (zh) * 2010-12-27 2013-11-20 武田药品工业株式会社 口腔崩解片剂
CN102716097A (zh) * 2012-05-29 2012-10-10 浙江华海药业股份有限公司 控制口腔崩解片药物释放速率的方法
FI126168B (en) 2012-09-18 2016-07-29 Novaldmedical Ltd Oy A method for coating pharmaceutical substrates
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
CA2964628A1 (en) 2014-10-20 2016-04-28 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
ES2700364T3 (es) * 2015-02-10 2019-02-15 Fujifilm Corp Comprimido de disgregación oral y método para su fabricación
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
EP3421032A4 (en) * 2016-02-23 2019-10-23 Nipro Corporation PARTICULARS OF A PHARMACEUTICAL COMPOSITION, ORAL DECOMPOSITION PREPARATION THEREOF AND METHOD FOR PRODUCING PARTICLES OF A PHARMACEUTICAL COMPOSITION
GB201607548D0 (en) * 2016-04-29 2016-06-15 Univ Central Lancashire Solid dosage form
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
JOP20190008A1 (ar) 2016-07-26 2019-01-24 Purdue Pharma Lp علاج ومنع اضطرابات النوم
JP7057287B2 (ja) * 2016-12-28 2022-04-19 富士フイルム富山化学株式会社 医薬組成物
KR102555664B1 (ko) * 2017-02-21 2023-07-18 이에이 파마 가부시키가이샤 과립 제제
JP7235193B2 (ja) * 2017-04-26 2023-03-08 大正製薬株式会社 固形組成物
JP7009288B2 (ja) * 2017-05-18 2022-01-25 エルメッド株式会社 湿製錠剤の製造方法及び湿製錠剤の品質向上方法
JP7336187B2 (ja) * 2017-11-30 2023-08-31 日本ケミファ株式会社 多層構造を有する粒子状医薬組成物
EP3740197A4 (en) 2018-01-16 2021-11-10 Applied Materials, Inc. METAL OXIDE ENCAPSULATED DRUG COMPOSITIONS AND METHODS FOR PREPARATION
JP7108041B2 (ja) 2018-01-24 2022-07-27 パーデュー、ファーマ、リミテッド、パートナーシップ 睡眠障害の治療及び予防
JP2021512924A (ja) * 2018-02-08 2021-05-20 タイワンジェ ファーマシューティカルズ カンパニー リミテッドＴａｉｗａｎｊ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｃｏ．， Ｌｔｄ． オピオイド受容体拮抗薬の固体剤形の医薬製剤
EP3917621A1 (en) 2019-01-31 2021-12-08 Purdue Pharma LP Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound
GB202001237D0 (en) * 2020-01-29 2020-03-11 Sisteks D O O Granular pharmaceutical product for oral administration from a pre-filled straw and method of manufacturing such pharmaceutical product
CA3168680A1 (en) 2020-01-31 2021-08-05 Nanocopoeia, Llc Amorphous nilotinib microparticles and uses thereof
CA3181361A1 (en) 2020-04-30 2021-11-04 Nanocopoeia, Llc Orally disintegrating tablet comprising amorphous solid dispersion of nilotinib
CN112121067A (zh) * 2020-11-16 2020-12-25 深圳科兴药业有限公司 一种婴儿型双歧杆菌微胶囊及其制备方法
WO2023182332A1 (ja) * 2022-03-22 2023-09-28 株式会社ダイセル 口腔内崩壊錠用の添加剤組成物

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62277322A (ja) 1986-02-13 1987-12-02 Takeda Chem Ind Ltd 安定化された腸溶性抗潰瘍固形組成物
CA1327010C (en) 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
FR2679451B1 (fr) 1991-07-22 1994-09-09 Prographarm Laboratoires Comprime multiparticulaire a delitement rapide.
US5464632C1 (en) 1991-07-22 2001-02-20 Prographarm Lab Rapidly disintegratable multiparticular tablet
SE9402431D0 (sv) 1994-07-08 1994-07-08 Astra Ab New tablet formulation
US6024981A (en) 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
US6096340A (en) 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
ES2559766T3 (es) 1998-05-18 2016-02-15 Takeda Pharmaceutical Company Limited Comprimidos disgregables en la boca
AR019935A1 (es) 1998-07-28 2002-03-27 Takeda Pharmaceutical Preparacion solida de desintegracion rapida, uso de una hidroxipropil celulosa poco sustituida en dicha preparacion y metodo para mejorar la capacidad dedesintegracion rapida de la misma
CA2346001C (en) 1998-10-01 2003-12-30 Elan Pharma International, Limited Controlled release nanoparticulate compositions
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI275587B (en) 1999-06-17 2007-03-11 Takeda Chemical Industries Ltd A crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
GB0025208D0 (en) 2000-10-13 2000-11-29 Euro Celtique Sa Delayed release pharmaceutical formulations
KR100507946B1 (ko) 2001-01-31 2005-08-17 룀 게엠베하 운트 콤파니 카게 상이하게 피복된 펠렛 형태를 두 가지 이상 포함하는 다중 입상형 약제
AU2002316020B2 (en) 2001-07-16 2007-03-15 Astrazeneca Ab Pharmaceutical formulation comprising a proton pump inhibitor and antacids
DE10208335A1 (de) 2002-02-27 2003-09-04 Roehm Gmbh Arzneiform und Verfahren zu ihrer Herstellung
AUPS167602A0 (en) 2002-04-12 2002-05-16 F.H. Faulding & Co. Limited An improved modified release preparation
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
JP4493970B2 (ja) 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
US20040096497A1 (en) 2002-11-19 2004-05-20 Ponder Garratt W. Methods of providing controlled-release pharmaceutical compositions and controlled-release pharmaceutical compositions
MXPA04010956A (es) 2003-01-30 2005-01-25 Roehm Gmbh Forma de dosis farmaceutica y metodo para la produccion de la misma.
US20060115529A1 (en) * 2003-05-07 2006-06-01 Seonghoon Jeong Fast-melting tablets having taste-masking and sustained release properties
KR20060065632A (ko) 2003-07-17 2006-06-14 닥터 레디스 래보러토리즈, 인코포레이티드 팽창성 코팅을 갖는 약제학적 조성물
NZ546183A (en) 2003-09-26 2011-04-29 Alza Corp Controlled release formulations exhibiting an ascending rate of release
GB0323232D0 (en) * 2003-10-03 2003-11-05 Rolls Royce Plc Electrical machine
US20070196396A1 (en) 2004-02-11 2007-08-23 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
US20050181052A1 (en) 2004-02-17 2005-08-18 Patel Satishkumar A. Lansoprazole microtablets
WO2005092297A2 (en) 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
JPWO2005084649A1 (ja) 2004-03-04 2007-11-29 武田薬品工業株式会社 安定なカプセル剤
US8545881B2 (en) 2004-04-19 2013-10-01 Eurand Pharmaceuticals, Ltd. Orally disintegrating tablets and methods of manufacture
CA2579767A1 (en) * 2004-04-30 2005-11-10 Astellas Pharma Inc. Oral pharmaceutical composition in timed-release particle form and fast-disintegrating tablets containing this composition
DE102004035936A1 (de) 2004-07-23 2006-03-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform
US20080063710A1 (en) 2004-12-28 2008-03-13 Eisai R&D Management Co., Ltd. Rapidly Disintegrating Tablet and Production Method Thereof
GB0502479D0 (en) 2005-02-07 2005-03-16 Sb Pharmco Inc Novel compositions
FR2885526B1 (fr) 2005-05-13 2007-07-27 Flamel Technologies Sa Medicament oral a base d'inhibiteur de pompe a protons
DE102005024614A1 (de) 2005-05-25 2006-11-30 Röhm Gmbh Verwendung von Polymermischungen zur Herstellung von überzogenen Arzneiformen sowie Arzneiform mit polymerem Mischüberzug
WO2006105798A2 (en) 2005-07-11 2006-10-12 Nycomed Danmark Aps Benzimidazole formulation
DE102005032806A1 (de) 2005-07-12 2007-01-18 Röhm Gmbh Verwendung eines teilneutralisierten, anionischen (Meth)acrylat-Copolymers als Überzug für die Herstellung einer Arzneiform mit einer Wirkstofffreisetzung bei erniedrigten pH-Werten
US20090148519A1 (en) 2005-09-29 2009-06-11 Yasuhiro Zaima Pulsed-release preparation having improved disintegration properties in vivo
FR2891459B1 (fr) 2005-09-30 2007-12-28 Flamel Technologies Sa Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
CN101340897A (zh) * 2005-12-20 2009-01-07 特瓦制药工业有限公司 兰索拉唑口腔崩解片剂
US20070141151A1 (en) 2005-12-20 2007-06-21 Silver David I Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
CA2633825A1 (en) 2005-12-20 2007-07-05 Teva Pharmaceutical Industries Ltd. Lansoprazole orally disintegrating tablets
CA2634232C (en) 2005-12-28 2013-08-20 Takeda Pharmaceutical Company Limited Method of producing solid preparation disintegrating in the oral cavity
KR100762847B1 (ko) 2006-01-27 2007-10-04 씨제이 주식회사 멀티플 유닛 타입 서방성 경구 제제 및 그 제조방법
EP1837016A3 (en) 2006-03-08 2008-01-02 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical multiple-unit composition
US20090068263A1 (en) 2006-04-20 2009-03-12 Themis Laboratories Private Limited Multiple unit compositions
US20090169617A1 (en) 2006-04-26 2009-07-02 Panagiotis Keramidas Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix
EP2015731B1 (en) 2006-04-28 2013-11-06 Wockhardt Limited Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, acetaminophen and proton pump inhibitor
JP2009541337A (ja) 2006-06-19 2009-11-26 マクニール−ピーピーシー・インコーポレーテツド 活性成分を含有する腸溶性の被覆された粒子
WO2008006534A2 (en) 2006-07-11 2008-01-17 Lek Pharmaceuticals D.D. Multiple unit tablets
US20090252787A1 (en) 2006-07-28 2009-10-08 Dr. Reddy's Laboratories Ltd. Granular pharmaceutical compositions
ES2547226T5 (es) 2006-08-30 2020-06-12 Jagotec Ag Formulaciones de dosificación oral de liberación controlada que comprenden un núcleo y una o más capas de barrera
EP2098250B1 (en) 2006-12-28 2016-09-28 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
DE102007009242A1 (de) * 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit magensaftresistenter Wirkstoff-Matix
DE102007009243A1 (de) 2007-02-22 2008-09-18 Evonik Röhm Gmbh Pellets mit einer Wirkstoff-Matrix und einem Polymerüberzug, sowie ein Verfahren zur Herstellung der Pellets
WO2008135090A1 (en) 2007-05-07 2008-11-13 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
UY31698A (es) 2008-03-11 2009-11-10 Takeda Pharmaceutical Preparacion solida de desintegracion oral
WO2010008569A1 (en) 2008-07-17 2010-01-21 Barr Laboratories, Inc. Orally disintegrating solid pharmaceutical dosage forms comprising delayed-release lansoprazole and methods of making and using the same
CN103402500A (zh) 2010-12-27 2013-11-20 武田药品工业株式会社 口腔崩解片剂

Also Published As

Publication number Publication date
US20150037423A1 (en) 2015-02-05
KR20100129761A (ko) 2010-12-09
CN102026627A (zh) 2011-04-20
JP5604304B2 (ja) 2014-10-08
AU2009224254A1 (en) 2009-09-17
PE20141034A1 (es) 2014-09-10
GEP20135845B (en) 2013-06-10
DOP2010000273A (es) 2010-09-30
MY173730A (en) 2020-02-18
WO2009113703A3 (en) 2010-06-17
NZ588407A (en) 2012-07-27
US9241910B2 (en) 2016-01-26
AU2009224254A2 (en) 2010-11-18
US20110091563A1 (en) 2011-04-21
CN104127368A (zh) 2014-11-05
CR11709A (es) 2010-11-04
MX2010009824A (es) 2010-09-28
ECSP10010538A (es) 2010-11-30
EP2254556A2 (en) 2010-12-01
CO6321224A2 (es) 2011-09-20
CN102026627B (zh) 2016-10-26
CA2717947C (en) 2020-07-07
AR070863A1 (es) 2010-05-12
MA32174B1 (fr) 2011-03-01
EA021792B1 (ru) 2015-09-30
IL207989A0 (en) 2010-12-30
TWI441658B (zh) 2014-06-21
TW200944249A (en) 2009-11-01
PE20091620A1 (es) 2009-11-12
WO2009113703A2 (en) 2009-09-17
CA2717947A1 (en) 2009-09-17
ZA201006679B (en) 2011-11-30
EA201071054A1 (ru) 2011-04-29
CL2009000557A1 (es) 2010-10-01
BRPI0909439A2 (pt) 2015-12-15
JP2011513204A (ja) 2011-04-28

Similar Documents

Publication Publication Date Title
UY31698A (es) Preparacion solida de desintegracion oral
CY1122575T1 (el) Φαρμακοτεχνικες μορφες διστρωματικου δισκιου
CU20130094A7 (es) Moduladores de la vía del complemento
CR20110110A (es) Composicion farmaceutica
MX350875B (es) Formas de dosificacion farmaceutica de liberacion controlada.
CL2012002944A1 (es) Compuestos derivados de amino-pirimidinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
CL2012002945A1 (es) Compuestos derivados de amino-piridazinas; composiciones farmacéuticas que los comprenden; y su uso para el tratamiento de una enfermedad afección seleccionada de trastornos neuromusculares, esclerosis lateral amiotrófica, miastenia grave, entre otras.
PE20080765A1 (es) Formas de dosificacion farmaceutica
EA201200937A1 (ru) Твердая лекарственная форма тикагрелора
BR112015018087A8 (pt) composto, composição farmacêutica e uso
ECSP099620A (es) Derivados de ciclohexano espirociclico
UY33075A (es) Derivados de ciclohexano y usos de los mismos
RS54238B1 (en) ORAL FILM FORMULATIONS CONTAINING DAPOXETINE AND TADALAFIL
EA201400737A1 (ru) Система доставки на основе множества пеллет с немедленным высвобождением активного вещества
MX2012013021A (es) Formulaciones resistentes a alcohol.
CR20190144A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos
UY33348A (es) Compuestos de furopiridina y usos de los mismos
CL2009001841A1 (es) Uso de una composición de liberación sostenida de 4-aminopiridina para preparar un medicamento útil para tratar esclerosis multiple en un sujeto.
CL2009001062A1 (es) Mezcla de barniz para revestir una forma farmaceutica de dosificacion solida que comprende a) agua (80 a 99% del peso total), b) un agente formador de pelicula (0,25 a 20% del peso total), y c) un agente de revestimiento (0,01 a 5% del peso total;) proceso de barnizado; forma farmaceutica solida .
UY31887A (es) Uso de dronedarona para la preparación de un medicamento para uso en la prevención de la cardioversión
PH12016500693B1 (en) Slow-release solid oral compositions
MY166972A (en) Transdermal delivery system containing galantamine or salts thereof
CR20190145A (es) Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
MD20150054A2 (ro) Produs de comicronizare cu conţinut de un modulator selectiv al receptorului de progesteron
EA201300079A3 (ru) Фармацевтическая композиция для пролонгированного высвобождения триметазидина

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181017